NGM

Analyst Sentiment

Wall St. Consensus
Buy
15 analysts·Moderate coverage
67
Score
10 Buy (67%)5 Hold (33%)0 Sell (0%)
Rating Breakdown
Strong Buy
00%
Buy
1067%
Hold
533%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$4.00
+159.7%
Consensus
$16.50
+971.4%
Bull
$29.00
+1783.1%
12-Month Target Range15 analysts
$4.00$16.50$29.00
Current $1.54Consensus
Current Price
$1.54
Upside to Consensus
$14.96

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev-17.04%
EPS
FY2028
Rev+142.23%
EPS
Raw consensus estimates (low / average / high) from covering analysts.
Annual
MetricFY2026EFY2027EFY2028E
Revenue Avg$36M$30M$72M
Low$36M$30M$72M
High$36M$30M$72M
EBITDA Avg$-32M$-27M$-64M
Low$-32M$-27M$-64M
High$-32M$-27M$-64M
EBIT Avg$-32M$-27M$-65M
Low$-32M$-27M$-65M
High$-32M$-27M$-65M
Net Income Avg$-35M$-64M$-51M
Low$-39M$-64M$-51M
High$-32M$-64M$-51M
EPS Avg$-0.43$-0.78$-0.62
Low$-0.47$-0.78$-0.62
High$-0.39$-0.78$-0.62
Analysts (Rev / EPS)4 / 22 / 11 / 1

Earnings Surprises

Recent Analyst Actions

Oct 17, 2022Raymond James
NGM Biopharmaceuticals cut at Raymond James, off ACF list after trial miss
Target:$4.00
+17.3%from $3.41
May 24, 2022Goldman Sachs
Goldman Sachs Maintains Buy on NGM Biopharmaceuticals, Lowers Price Target to $29
Target:$29.00
+112.6%from $13.64
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.